Prevalence of NAFLD in T2DM Patients
Launched by ZIEKENHUIS OOST-LIMBURG · Jun 3, 2024
Trial Information
Current as of March 14, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years of age
- • Having type 2 diabetes mellitus (T2DM)
- • Written informed consent obtained
- Exclusion Criteria:
- • Excessive alcohol use
- • Exclusion of other causes of liver disease and secondary causes of steatosis
Trial Officials
Mathieu Struyve, MD
Principal Investigator
Ziekenhuis Oost-Limburg
About Ziekenhuis Oost Limburg
Ziekenhuis Oost-Limburg (ZOL) is a leading healthcare institution in Belgium, dedicated to providing high-quality medical care and advancing clinical research. With a commitment to patient-centered practices, ZOL integrates innovative research within its healthcare services, fostering collaboration among multidisciplinary teams to enhance treatment outcomes. The hospital actively conducts clinical trials across various medical fields, aiming to contribute valuable insights to the scientific community and improve therapeutic options for patients. Through its robust research initiatives, ZOL strives to remain at the forefront of medical advancements while ensuring the highest standards of safety and ethical practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genk, Limburg, Belgium
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
